CJC-1295
A modified GHRH analog engineered specifically to solve GHRH's biggest practical limitation — its native half-life of just a few minutes — using a chemical trick that lets it hitch a ride on circulating albumin.
Available from KYIN Peptides as part of our CJC-1295 + Ipamorelin Blend — see availability below.
What Is CJC-1295?
CJC-1295 is a modified analog of growth-hormone-releasing hormone, built on the same GHRH(1-29) backbone as Sermorelin but with additional amino acid substitutions for protease resistance, plus a Drug Affinity Complex (DAC) — a maleimidopropionic acid linker that reacts with a free thiol group on circulating albumin, covalently attaching the peptide to it. That albumin binding is what gives CJC-1295 its defining property: an estimated half-life of 5.8–8.1 days, versus the few minutes native GHRH or Sermorelin last in circulation.
This is also a common source of confusion in the research-peptide space: what's sold as "CJC-1295 without DAC" is a related but distinct, shorter-acting peptide (often called Mod GRF 1-29) that lacks the albumin-binding modification entirely — it is not simply CJC-1295 minus one feature, but a different compound with a very different duration of action.
Research Focus
CJC-1295 sits alongside Tesamorelin as one of KYIN's two GHRH-analog compounds, engineered for the same underlying reason: extending native GHRH's stimulation of the growth hormone axis. See our GHRH & Growth Hormone research overview for how it fits alongside Tesamorelin, Ipamorelin, and Sermorelin, our full CJC-1295 vs Tesamorelin vs Ipamorelin vs Sermorelin comparison, or the head-to-head pages CJC-1295 vs Ipamorelin and Tesamorelin vs CJC-1295. See also its full discovery history.
Clinical & Preclinical Trial Data
CJC-1295 has been tested in humans more extensively than most compounds referenced on this site. The pivotal study (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006; 65 healthy adult subjects) found a single injection produced a dose-dependent GH increase of 2–10× baseline sustained for at least 6 days, and an IGF-1 increase of 1.5–3× baseline sustained for 9–11 days — consistent with the compound's estimated 5.8–8.1-day half-life. With repeated dosing, mean IGF-1 remained above baseline for up to 28 days, and the compound was well tolerated with no serious adverse events reported.
A separate study (Ionescu & Frohman, Journal of Clinical Endocrinology & Metabolism, 2006) examined healthy men receiving a single CJC-1295 injection with overnight GH sampling before and one week after. GH secretion increased with preserved pulsatility — the frequency and magnitude of GH pulses were unaltered — but trough (basal) GH levels rose 7.5-fold, contributing to a 46% increase in mean GH secretion and a 45% increase in IGF-1.
CJC-1295 with DAC is investigational and is not FDA-approved for any indication. See its full discovery history for how its clinical development played out.
Availability
CJC-1295 is available from KYIN Peptides as part of our CJC-1295 + Ipamorelin Blend — see the product page for current pricing and specifications.
CJC-1295 questions
What is CJC-1295?
CJC-1295 is a modified GHRH analog developed by ConjuChem Biotechnologies using Drug Affinity Complex (DAC) technology — a chemical linker that lets the peptide bind covalently to circulating albumin, extending its half-life from the few minutes seen with native GHRH to an estimated 5.8–8.1 days.
Is "CJC-1295 without DAC" the same thing as CJC-1295?
No, and this is a common point of confusion. "CJC-1295" properly refers to the DAC-modified, long-acting compound from the original ConjuChem research. "CJC-1295 without DAC" is a related but distinct, shorter-acting peptide (often also called Mod GRF 1-29) that lacks the albumin-binding modification entirely.
How is CJC-1295 different from Sermorelin?
Sermorelin is the unmodified GHRH(1-29) fragment — it has full native bioactivity but is cleared from circulation within minutes. CJC-1295 is a structurally modified version of that same GHRH signal, engineered specifically to resist rapid degradation and extend its duration of action to days rather than minutes.
Has CJC-1295 been tested in humans?
Yes. A study of 65 healthy adult subjects (Teichman et al., 2006) found single-injection CJC-1295 produced a dose-dependent GH increase of 2–10x baseline sustained for at least 6 days, and an IGF-1 increase of 1.5–3x baseline sustained for 9–11 days. It is not FDA-approved for any indication.
Does KYIN Peptides sell CJC-1295?
Yes — CJC-1295 is available from KYIN Peptides as part of our CJC-1295 + Ipamorelin Blend. See the product page for current pricing and specifications.
Looking for CJC-1295 specs and pricing?
View purity, available sizes, and pricing on the blend product page.